Decreased expression of miR‑490‑3p in colorectal cancer predicts poor prognosis and promotes cell proliferation and invasion by targeting RAB14

Wang,Bo; Yin,Mujun; Cheng,Cheng; Jiang,Hongpeng; Jiang,Kewei; Shen,Zhanlong; Ye,Yingjiang; Wang,Shan

doi:10.3892/ijo.2018.4444

Decreased expression of miR‑490‑3p in colorectal cancer predicts poor prognosis and promotes cell proliferation and invasion by targeting RAB14

Authors:
- Bo Wang
- Mujun Yin
- Cheng Cheng
- Hongpeng Jiang
- Kewei Jiang
- Zhanlong Shen
- Yingjiang Ye
- Shan Wang
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, P.R. China, Department of General Surgery, First Hospital of Qinhuangdao, Hebei 066000, P.R. China
Published online on: June 19, 2018 https://doi.org/10.3892/ijo.2018.4444
Pages: 1247-1256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Growing evidence indicates a potential role for miR‑490‑3p in tumorigenesis. However, its function in colorectal carcinoma (CRC) remains undefined. In this study, miR‑490‑3p was markedly downregulated in fifty colorectal cancer tissue samples compared with the corresponding adjacent non‑cancerous specimens, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The expression levels of miR‑490‑3p were closely associated with tumor differentiation and distant metastasis. In addition, both Kaplan-Meier and multivariate analyses indicated CRC patients with elevated miR‑490‑3p amounts had prolonged overall survival. Overexpression of miR‑490‑3p markedly reduced proliferation, colony formation and invasion in CRC cells by enhancing apoptosis and promoting G2/M phase arrest. Furthermore, ectopic expression of miR‑490‑3p resulted in decreased expression of RAB14, which was directly targeted by miR‑490‑3p, as shown by the dual-luciferase reporter gene assay. Finally, in a nude mouse model, miR‑490‑3p overexpression significantly suppressed the growth of CRC cells. The above results indicated that miR‑490‑3p might constitute a prognostic indicator and a novel molecular target for miRNA-based CRC therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Fakih MG: Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 33:1809–1824. 2015. View Article : Google Scholar : PubMed/NCBI
3	Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 10:513–525. 2009. View Article : Google Scholar : PubMed/NCBI
4	Reiner DJ and Lundquist EA: Small GTPases. WormBook 1.67.2. 1–99. 2016.
5	Hou R, Jiang L, Yang Z, Wang S and Liu Q: Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway. Tumour Biol. 37:16005–16013. 2016. View Article : Google Scholar
6	Sun J, Feng X, Gao S and Xiao Z: microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14. Mol Med Rep. 11:1400–1406. 2015. View Article : Google Scholar
7	Yu J, Wang L, Yang H, Ding D, Zhang L, Wang J, Chen Q, Zou Q, Jin Y and Liu X: Rab14 suppression mediated by miR-320a inhibits cell proliferation, migration and invasion in breast cancer. J Cancer. 7:2317–2326. 2016. View Article : Google Scholar : PubMed/NCBI
8	Li Y, Liu H, Shao J and Xing G: miR-320a serves as a negative regulator in the progression of gastric cancer by targeting RAB14. Mol Med Rep. 16:2652–2658. 2017. View Article : Google Scholar : PubMed/NCBI
9	Guo B, Wang W, Zhao Z, Li Q, Zhou K, Zhao L, Wang L, Yang J and Huang C: Rab14 act as oncogene and induce proliferation of gastric cancer cells via AKT signaling pathway. PLoS One. 12:e01706202017. View Article : Google Scholar : PubMed/NCBI
10	Kasinski AL and Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
11	Valeri N, Croce CM and Fabbri M: Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics. 6:195–204. 2009.PubMed/NCBI
12	Shen Z, Zhou R, Liu C, Wang Y, Zhan W, Shao Z, Liu J, Zhang F, Xu L, Zhou X, et al: MicroRNA-105 is involved in TNF-α-related tumor microenvironment enhanced colorectal cancer progression. Cell Death Dis. 8:32132017. View Article : Google Scholar
13	Shen ZL, Wang B, Jiang KW, Ye CX, Cheng C, Yan YC, Zhang JZ, Yang Y, Gao ZD, Ye YJ, et al: Downregulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling. Oncotarget. 7:35092–35105. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wang B, Shen ZL, Gao ZD, Zhao G, Wang CY, Yang Y, Zhang JZ, Yan YC, Shen C, Jiang KW, et al: miR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 14:1046–1058. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang B, Shen ZL, Jiang KW, Zhao G, Wang CY, Yan YC, Yang Y, Zhang JZ, Shen C, Gao ZD, et al: MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism. BMC Cancer. 15:4372015. View Article : Google Scholar : PubMed/NCBI
16	Zhang LY, Liu M, Li X and Tang H: miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 288:4035–4047. 2013. View Article : Google Scholar :
17	Shen J, Xiao Z, Wu WK, Wang MH, To KF, Chen Y, Yang W, Li MS, Shin VY, Tong JH, et al: Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Res. 75:754–765. 2015. View Article : Google Scholar
18	Qu M, Li L and Zheng WC: Reduced miR-490-3p expression is associated with poor prognosis of Helicobacter pylori induced gastric cancer. Eur Rev Med Pharmacol Sci. 21:3384–3388. 2017.PubMed/NCBI
19	Chen S, Chen X, Xiu YL, Sun KX and Zhao Y: MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumori-genesis and progression. Cancer Lett. 362:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
20	Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, Cheng K and Zou W: miR-490-3p inhibits the growth and invasiveness in triple- negative breast cancer by repressing the expression of TNKS2. Gene. 593:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
21	Liu W, Xu G, Liu H and Li T: MicroRNA-490-3p regulates cell proliferation and apoptosis by targeting HMGA2 in osteo-sarcoma. FEBS Lett. 589B:3148–3153. 2015. View Article : Google Scholar
22	Xu X, Chen R, Li Z, Huang N, Wu X, Li S, Li Y and Wu S: MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFβR1. BMC Cancer. 15:10232015. View Article : Google Scholar
23	Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M, Shao Z, Zhang F, Luo Y, Shen Z, et al: Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/β-catenin signaling pathway. Cancer Lett. 376:178–187. 2016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ: Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001. View Article : Google Scholar
25	Bracken CP, Scott HS and Goodall GJ: A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
26	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvi-ronment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
27	Profumo V and Gandellini P: MicroRNAs: Cobblestones on the road to cancer metastasis. Crit Rev Oncog. 18:341–355. 2013. View Article : Google Scholar : PubMed/NCBI
28	Shen Z, Wang B, Luo J, Jiang K, Zhang H, Mustonen H, Puolakkainen P, Zhu J, Ye Y and Wang S: Global-scale profiling of differential expressed lysine acetylated proteins in colorectal cancer tumors and paired liver metastases. J Proteomics. 142:24–32. 2016. View Article : Google Scholar : PubMed/NCBI
29	Doldi V, Pennati M, Forte B, Gandellini P and Zaffaroni N: Dissecting the role of microRNAs in prostate cancer metastasis: Implications for the design of novel therapeutic approaches. Cell Mol Life Sci. 73:2531–2542. 2016. View Article : Google Scholar : PubMed/NCBI
30	White NM, Fatoohi E, Metias M, Jung K, Stephan C and Yousef GM: Metastamirs: A stepping stone towards improved cancer management. Nat Rev Clin Oncol. 8:75–84. 2011. View Article : Google Scholar
31	Gandellini P, Doldi V and Zaffaroni N: microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Semin Cancer Biol. 44:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
32	Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka H, Boland CR and Goel A: Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut. 66:654–665. 2017. View Article : Google Scholar
33	Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 60:598–609. 2014. View Article : Google Scholar : PubMed/NCBI
34	Tian J, Xu YY, Li L and Hao Q: miR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res. 9:1127–1138. 2017.PubMed/NCBI
35	Takai Y, Sasaki T and Matozaki T: Small GTP-binding proteins. Physiol Rev. 81:153–208. 2001. View Article : Google Scholar : PubMed/NCBI
36	Jung B, Staudacher JJ and Beauchamp D: Transforming growth factor β superfamily signaling in development of colorectal cancer. Gastroenterology. 152:36–52. 2017. View Article : Google Scholar
37	Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
38	Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
39	Wang JL, Qi Z, Li YH, Zhao HM, Chen YG and Fu W: TGFβ induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/β-catenin signaling. Oncotarget. 8:70214–70225. 2017.PubMed/NCBI
40	Ma F, Li W, Liu C, Li W, Yu H, Lei B, Ren Y, Li Z, Pang D and Qian C: miR-23a promotes TGF-β1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/β-catenin signaling. Oncotarget. 8:69538–69550. 2017.PubMed/NCBI
41	Gillespie J, Ross RL, Corinaldesi C, Esteves F, Derrett-Smith E, McDermott MF, Doody GM, Denton CP, Emery P and Del Galdo F: Transforming growth factor β activation primes canonical Wnt signaling through down-regulation of Axin-2. Arthritis Rheumatol. 70:932–942. 2018. View Article : Google Scholar : PubMed/NCBI
42	Mitchell H, Choudhury A, Pagano RE and Leof EB: Ligand- dependent and -independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell. 15:4166–4178. 2004. View Article : Google Scholar : PubMed/NCBI